Deutsche Bank’s Galmed Pharmaceuticals GLMD Stock Holding History

Deutsche Bank’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-26	Closed	-$26K	–	4512
2019 Q4	$26K	Buy	+26	New	+$22.3K	﹤0.01%	4215
2019 Q3	–	Sell	-179	Closed	-$180K	–	5039
2019 Q2	$237K	Sell	179 -3	-2%	-$3.87K	﹤0.01%	3723
2019 Q1	$267K	Sell	182 -5	-3%	-$7.27K	﹤0.01%	3829
2018 Q4	$229K	Buy	+187	New	+$327K	﹤0.01%	3803
2018 Q2	–	Sell	-398	Closed	-$398K	–	5481
2018 Q1	$398K	Buy	398 +248	+165%	+$361K	﹤0.01%	3835
2017 Q4	$246K	Buy	+150	New	+$222K	﹤0.01%	3938
2016 Q3	–	Sell	-29	Closed	-$23K	–	5024
2016 Q2	$23K	Buy	+29	New	+$27.4K	﹤0.01%	4714
2015 Q2	–	Sell	-17	Closed	-$29K	–	5381
2015 Q1	$29K	Buy	+17	New	+$25.5K	﹤0.01%	4555
2014 Q3	–	Sell	-111	Closed	-$194K	–	5952
2014 Q2	$194K	Hold	111	–	–	﹤0.01%	4147
2014 Q1	$229K	Buy	+111	New	+$260K	﹤0.01%	3822

Other funds holding GLMD

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

RCG

Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

Deutsche Bank's GLMD Position: Q1 2020 in Review

Deutsche Bank sold out of Galmed Pharmaceuticals (GLMD) in Q1 2020, closing a stake of 26 shares — an estimated $26K sold.

Deutsche Bank first reported a position in GLMD in Q1 2014 and held it in 10 quarters. The position peaked at $398K in Q1 2018. 31 funds tracked by Wall St. Rank hold GLMD as of Q1 2020.

Deutsche Bank reported no remaining Galmed Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Deutsche Bank sold 26 Galmed Pharmaceuticals shares in Q1 2020, an estimated $26K.
Deutsche Bank first reported a position in Galmed Pharmaceuticals in Q1 2014 and held it in 10 quarters.
Deutsche Bank's Galmed Pharmaceuticals position peaked at $398K in Q1 2018.
31 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2020.

Based on Deutsche Bank's 13F filing for Q1 2020, filed 14 May 2020.